Generation of uncommitted human IPSC derived muscle stem cells for therapeutic applications
Dr. Florian Bentzinger, Nestlé Institute of Health Sciences, Campus EPFL, Lausanne
Abstract (Lay summary see below)
Stem cell therapy of skeletal muscle diseases is hindered by the limited availability of sufficient donor stem cells. This problem is complicated by the fact that primary muscle stem cells can currently not be expanded in vitro because removal of the cells from their niche induces their terminal commitment to myogenic differentiation. Upon transplantation, committed cells can only inefficiently engraft into the stem cell compartment and the majority of cells will differentiate and fuse into muscle fibers close to the injection site. This leads to poor distribution of muscle fibers containing donor nuclei in the host tissue and to transient effects that disappear with turnover of muscle fibers. Thus, by allowing for efficient engraftment into the stem cell compartment, the availability of large quantities of uncommitted cells would be a great advancement for the therapy of degenerative diseases of the skeletal musculature with a genetic basis.
Here we propose a screen for the derivation of uncommitted muscle stem cells from human induced pluripotent stem cells (hIPSCs). For this purpose we will generate fluorescent reporter hIPSC lines for the myogenic lineage markers Six1, Six4, Pax3, Pax7, Myf5, MyoD and Myogenin using the CRISPR technology. In contrast to current protocols for the derivation of myogenic cells from IPSCs, we will focus on conditions that allow for the derivation of uncommitted cells maintaining the expression of the stem cell markers but remaining negative for the commitment factors Myf5 and MyoD, as well as for the differentiation marker Myogenin.
Finally, we will test the engraftment and differentiation potential of muscle stem cells generated under candidate conditions in dystrophic mdx mice. Ultimately, our experiments will provide a much needed protocol for the derivation of uncommitted muscle stem cells from hIPSCs for therapeutic applications.
Lay summary
Aufgrund der limitierten Verfügbarkeit von Spenderzellen ist die Stammzelltherapie genetisch bedingter Krankheiten der Skelettmuskulatur momentan nicht möglich. Eine gezielte Vermehrung von Muskelstammzellen durch Zellkultur könnte ausreichend Spenderzellen generieren. Diese Strategie scheitert jedoch bisher daran, dass Muskelstammzellen die aus ihrer spezialisierten Gewebsnische entnommen werden schnell ihren Stammzellcharakter verlieren. Folglich können kultivierte Muskelvorläuferzellen nach der Transplantation das Empfängergewebe nicht als Stammzellen besiedeln, sondern nur als vor-differenzierte Zellen, die rasch im Bereich der Injektionsstelle mit den umliegenden Muskelfasern fusionieren. Dies führt dazu, dass die Verteilung modifizierter Muskelfasern mit Spenderzellkernen sehr inhomogen ist. Des Weiteren werden diese wenigen Fasern in der zytotoxischen Umgebung erkrankter Muskeln schnell eliminiert. Aus diesen Gründen wäre die ausreichende Verfügbarkeit undifferenzierter Muskelstammzellen ein entscheidender Fortschritt für die Therapie degenerativer Erkrankungen der Skelettmuskulatur. Solche Zellen könnten sich als Stammzellen im gesamten Empfängermuskel verteilen, würden lebenslang erhalten bleiben und könnten gleichzeitig konstant Tochterzellen bilden, die differenzieren und mit dem Empfängerfasern fusionieren. In unserem Projekt werden wir untersuchen, wie aus kultivierbaren menschlichen induzierten pluripotenten Stammzellen (IPS) undifferenzierte Muskelstammzellen generiert werden können. Zu diesem Zweck modifizieren wir IPS Zellen mit fluoreszierenden „Marker“ Proteinen, die uns während der Erzeugung der Muskelvorläuferzellen anzeigen ob die Zellen noch Stammzellcharakter haben oder bereits differenziert sind. Basierend auf dieser innovativen Strategie werden wir ein Protokoll etablieren, welches es ermöglicht grosse Mengen therapeutisch wertvoller Muskelstammzellen zu produzieren.
Projets
- Nouveaux projets de recherche dès 2024
- L'importance de la recherche
- Projets financés
- Unstructured proteins as therapeutic targets for neuromuscular diseases
- Open and reproducible pipeline for the acquisition and analysis of muscle MRI data in Facioscapulohumeral Muscular Dystrophy
- Dissecting lysosomal signals to fight Pompe disease
- Functional properties and epigenetic signature of quiescent and early activated human muscle reserve cells
- Activation of human skeletal muscle stem cells:role of Orai3 ans its partner AHNAK2 in physiological condition and in Duchenne Muscular Dystrophy
- Understanding the clinical spectrum associated with VMA21 deficiency
- ANTXR2 as a key player in Collagen VI signaling in muscle stem cells: new therapeutic perspectives for COL6-related myopathies.
- Molecular mechanisms of complement activation and neuromuscular disruption by combinations of autoantibodies from patients with Myasthenia Gravis
- From the investigation of the role of SRSF1 in ALS/FTD to its targeting as a therapeutic strategy
- Molecular crosstalk between muscles and motor neurons and its role in neuromuscular circuit formation
- Molecular Diagnosis and Coping Mechanisms in Mitochondrial Myopathies
- IPRIMYO: Immune-privileged, immortal, myogenic stem cells for gene therapy of Muscular Dystrophy
- Effect of RYR1 mutations on muscle spindle function and their impact on the musculoskeletal system
- Therapeutic potential of human myogenic reserve cells in Duchenne Muscular Dystrophy
- Glutamine metabolism as a potential target for Duchenne Muscular Dystrophy
- Targeting protein s-acylation during Tubular Aggregate Myopathy
- Aggravating the phenotype of dystrophic mice for improving preclinical research and clinical translation for Duchenne muscular dystrophy
- Characterization of autoreactive T cells in Guillain-Barré syndrome
- A vascularized human muscle-on-a-chip to elucidate the contribution of endothelial-mesenchymal transition on the progression of muscular dystrophies
- Characterization of a novel form of ALS associated with changes in the sphingolipid metabolism
- Pre-clinical treatment of mouse models carrying recessive Ryr1 mutations with HDAC/DNA methyltransferase inhibitors.
- New aspects of TGFβ signaling in muscle homeostasis and regeneration
- Inhibition of sphingolipid synthesis as a treatment strategy for Duchenne muscular dystrophy
- Tamoxifen in Duchenne muscular dystrophy (TAMDMD)
- DNA aptamers against the DUX4 protein reveal novel therapeutic implications for FSHD
- Facilitating diagnosis of critical illness myopathy using muscle excitability testing
- Rapid Exploratory Imaging for High-resolution and Whole Extremity Coverage in MR Neurography
- Deciphering novel mechanisms and effectors contributing to muscle dysfunction in Myotonic Dystrophy Type I
- Can HDAC/DNA methyltransferase inhibitors improve muscle function in a congenital myopathy caused by recessive RYR1 mutations?
- Identification of the critical regulators of protein synthesis and degradation in human muscle atrophy
- Exploring peripheral B-cell-helper T cell phenotypes in the blood of patients with Myasthenia gravis using mass cytometry (CyTOF)
- Molecular signature, metabolic profile and therapeutic potential of human myogenic reserve cells
- A multicenter cross-sectional and longitudinal study of the Swiss cohort of Merosin-negative congenital muscular dystrophy
- Targeting NADPH oxidase 4 in models of Duchenne muscular dystrophy
- Characterizing the role of ER stress in C9orf72-linked ALS pathology
- Inducing mitophagy with Urolithin A to restore mitochondrial and muscle function in muscular dystrophy
- Motor unit action potentials analysis in patients with myopathies with a new wireless portable and multichannel Surface EMG device (WPM-SEMG)
- Role and therapeutic potential of PLIN3 in neuromuscular diseases
- Changes in ventilation distribution in children with neuromuscular disease using the insufflator/exsufflator technique: An observational study
- Mechanism and function of genome organization in muscle development and integrity
- Role and therapeutic potential of NADPH oxidases in a mouse model of Duchenne Muscular Dystrophy
- Characterization of pathological pathways activated in muscles of patients with congenital myopathies with disturbed Ca2+ homeostasis
- Creation of a study team to conduct an SMA 1-clinical trial at the Centre for Neuromuscular Diseases of the University Children's Hospital Basel (UKBB)
- Novel treatment to stop progressive neuropathy and muscle weakness in multifocal motor neuropathy
- Understanding the pathomechanisms leading to muscle alterations in Myotonic Dystrophy type I
- Automated volumetry and quantitative MRI to diagnose peripheral nerve lesions – translational proposal for a new clinical diagnostic imaging tool
- Novel approaches against Spinal Muscular Atrophy by targeting splicing regulators
- Protective effects and mechanisms of action of tamoxifen in mice with severe muscular diseases
- Role of the receptor FgfrL1 in the development of slow muscle fibers
- Muscle velocity recovery cycles: A new tool for early diagnosis of critical illness myopathy
- Generation of uncommitted human IPSC derived muscle stem cells for therapeutic applications
- Transposable vectors for dystrophin-expression in a murine model for muscular dystrophy
- Cardiac involvement in patients with Duchenne/Becker Muscular Dystrophy; an observational study
- Deciphering the pathogenic mechanisms of C9ORF72 ALS
- Enhancing estrogenic signalling to fight muscular dystrophies: Mechanisms of action and repurposing clinically approved drugs
- Mechanisms and therapeutic potential of modulating PGC‐1α to alter neuromuscular junction morphology and function
- Triggering human myoblast differentiation: from EGFR to myogenic transcription factors
- Improving cellular therapies of muscle dystrophies by uncovering epigenetic and signaling pathways of muscle formation
- Protein engineering in an attempt to increase the mechanical, integrin dependent cytoskeleton-matrix linkage in muscle fibers
- Muscle velocity recovery cycles: a new tool for characterization of muscle disease in vivo
- Excessive neurotrypsin activation and agrin cleavage-a pathogenic condition leading to sarcopenia-like muscle atrophy?
- Evaluation of novel treatment strategies for dyspherlinopathies in mouse models
- Cell therapy of LGMD2D by donor HLA-characterized human mesoangioblasts (hMABs) produced in GMP conditions
- In search of small molecules targeting protein-RNA complex: a novel approach against Spinal Muscular Atrophy
- Restoration of autophagy as a new strategy for the treatment of congenital muscular dystrophies
- Development of magnetic resonance methods for functional imaging of the skeletal muscle
- Targeting ER stress response: a potential mechanism for neuroprotection in Amyotrophic Lateral Sclerosis
- Generation of uncommitted human IPSC derived muscle stem cells for therapeutic applications
- Brochure décrivant les projets
- SEAL Therapeutics AG
- Rencontres et séminaires
- Participation à des associations faîtières
- Les registres de patients
- Le réseau Myosuisse
FSRMM
- Chemin des Saules 4B
2013 Colombier - +41 78 629 63 92
- philippe.rognon@fsrmm.ch